PO.TB04.08 · 肿瘤生物学
利用共聚焦活细胞成像评估复杂肿瘤学模型中的治疗疗效和毒性
Utilizing confocal live-cell imaging for evaluating therapeutic efficacy and toxicity in complex oncology models
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
肿瘤学研究持续朝着利用更复杂、更具转化价值的细胞模型发展,以改善临床结局。与之并行,能够从日益复杂的数据中获得清晰见解的互补生物分析工具的需求也在不断演进。Incucyte® CX3能够在生理相关条件下对复杂肿瘤模型和类器官进行多平面、旋转盘共聚焦成像。本海报将重点介绍这项技术与集成分析工具相结合,用于评估治疗化合物的疗效和脱靶毒性的应用。首先在实体瘤模型中评估了化疗化合物的效应。例如,将稳定表达核定位绿色荧光蛋白的MCF7细胞包埋于细胞外基质中,并在荧光染料存在下接种以监测凋亡。监测球状体形成3天,然后测试喜树碱(0.3-10 μM)或顺铂(3-100 μM)的效应。对共聚焦最大投影图像进行的自动分析显示,球状体生长呈浓度依赖性下降,并伴随凋亡的相应增加。许多化疗药物在临床病例中被观察到可诱导肝毒性。因此,还在肝毒性模型中测量了化合物的效应。将稳定表达核定位橙色荧光蛋白的小鼠肝类器官以与癌症球状体类似的方式接种。在形成期间(1天)以及药物处理后额外的四天内,每8小时采集一次共聚焦多平面图像。喜树碱和顺铂随时间诱导浓度依赖性的生长下降,高浓度(分别为5-10 μM或50-100 μM)诱导凋亡。重要的是,共聚焦成像实现的毒性荧光读出更为灵敏,因为通过明场读出难以将细胞碎片与健康类器官区分开来。还评估了免疫细胞与癌细胞的共培养模型。将SKOV-3 Nuclight Orange球状体与一定密度范围的活化(10 ng/mL CD3/CD28处理72小时)或非活化PBMC,在Fabfluor-488-CD45或Fabfluor-488-IgG1以及optigreen背景抑制剂存在下接种。使用共聚焦多平面采集对共培养进行6天成像。结果显示,对于活化的PBMC,随着PBMC密度增加,橙色面积呈密度依赖性下降,表明靶细胞死亡。此外,在免疫介导的肿瘤杀伤之后,我们观察到随着PBMC扩增,绿色面积呈密度依赖性增加。综上所述,这些数据凸显了多参数、多平面共聚焦活细胞分析能够从多种复杂的临床前模型(包括免疫肿瘤学和基于类器官的毒性读出)中提供清晰、快速见解的能力。
查看英文原文 English abstract
Oncology research continues to progress towards utilizing more complex, translational cellular models to improve clinical outcomes. The need for complementary bioanalytical tools to enable clear insights from increasingly complex data has evolved in parallel. The Incucyte® CX3 enables multiplane, spinning disk confocal imaging of complex tumor models and organoids under physiologically relevant conditions. This poster will highlight the application of this technology, paired with integrated analysis tools, to evaluate the efficacy and off-target toxicity of therapeutic compounds. The effects of chemotherapeutic compounds were first evaluated in solid tumor models. For example, MCF7 cells stably expressing a nuclear-restricted green fluorescent protein were embedded in extracellular matrix and plated in the presence of a fluorescent dye to monitor apoptosis. Spheroid formation was monitored for 3 days, then the effects of camptothecin (0.3 - 10 µM) or cisplatin (3 - 100 µM) were tested. Automated analysis performed on confocal max projection images revealed a concentration-dependent decrease in spheroid growth and complementary increase in apoptosis. Many chemotherapeutic agents have been observed to induce hepatotoxicity in clinical cases. Therefore, the effects of compounds were also measured in a model of liver toxicity. Mouse hepatic organoids stably expressing a nuclear-restricted orange fluorescent protein were plated in a similar manner to cancer spheroids. Confocal multiplane images were acquired every 8 hours during formation (1 day) and for an additional four days following drug treatment. Camptothecin and cisplatin induced a concentration-dependent decrease in growth over time, with high concentrations (5-10 µM or 50-100 µM, respectively) inducing apoptosis. Importantly, fluorescent readouts of toxicity enabled by confocal imaging were more sensitive, as cellular debris can be difficult to distinguish from healthy organoids via brightfield readouts. Immune- and cancer-cell coculture models were also evaluated. SKOV-3 Nuclight Orange spheroids were seeded with a density range of activated (10 ng/mL CD3/CD28 for 72 hours) or non-activated PBMCs in the presence of Fabfluor-488-CD45 or Fabfluour-488-IgG1 and optigreen background suppressor. Co-cultures were imaged over 6 days using confocal multiplane acquisition. The results showed a density-dependent decrease in orange area with increasing PBMC density for activated PBMCs, indicating target cell death. Additionally, following immune-mediated tumor killing, we observed a density-depending increase in green area with PBMCs expansion. Taken together, these data highlight the ability of multiparameter, multiplane confocal live cell analysis to provide clear, rapid insights from a variety of complex pre-clinical models, including immuno-oncology and organoid-based toxicity readouts.
利益披露 Disclosure
J. Rauch, None..
J. Bezenah, None..
L. Oupicka, None..
R. Lister, None..
L. Skerlos, None.